Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Bm_squib
CORGARETIC - 80 TABLETS CORGARETIC - 40 TABLETS SCHEDULING STATUS: S3 APPROVED PP ZIMBABWE ONLY PROPRIETARY NAME (and dosage form) CORGARETIC - 80 TABLETS CORGARETIC - 40 TABLETS COMPOSITION CORGARETIC-80 tablets contain 80 mg of nadolol ; 2,3 Cis-1,2,3,4- tetrahydro-5- [2-hydroxy-3- (tert-butyl-amino) propoxy] -2,3- naphthalenediol in combination with 5 mg bendroflumethiazide ; 3-benzyl-3,4-dihydro-6- (trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide. CORGARETIC-40 tablets contain 40 mg of nadolol; 2,3 Cis-1,2,3,4- tetrahydro-5- [2-hydroxy-3- (tert-butyl-amino) propoxy] -2,3- naphthalenediol in combination with 5 mg bendroflumethiazide; 3-benzyl-3,4-dihydro-6- (trifluoromethyl)-2H-1,2,4-benzothia diazine-7-sulphonamide 1,1-dioxide. PHARMACOLOGICAL CLASSIFICATION Category A 7.1.3 Other Hypotensives PHARMACOLOGICAL ACTION CORGARETIC is an antihypertensive which combines nadolol, a non-selective beta-adrenergic receptor blocking agent, and bendroflumethiazide, a diuretic/antihypertensive. Nadolol and bendroflumethiazide produce an additive therapeutic effect in reducing elevated blood pressure. INDICATIONS Hypertension. CONTRA-INDICATIONS ALLERGY TO ANY OF THE COMPONENTS Nadolol is contra-indicated for patients with bronchial asthma; chronic respiratory diseases; allergic rhinitis during the pollen season; sinusbradycardia; cardiogenic shock and all degrees of heart block greater than first degree AV block and bradycardia less than 50 per minute; right ventricular failure secondary to pulmonary hypertension; congestive heart failure (see Warnings); patients receiving adrenergic-augmenting psychotropic drugs (including MAO inhibitors), and during a two-week withdrawal period from such drugs, peripheral vascular diseases and Raynaud's phenomenon; heart failure; renal failure and hepatic failure. WARNINGS NADOLOL Caut Read the complete document